Research programme: targeted protein degradation therapeutics - C4 Therapeutics
Latest Information Update: 15 Jan 2016
At a glance
- Originator C4 Therapeutics
- Developer Dana-Farber Cancer Institute
- Class Small molecules
- Mechanism of Action Ubiquitin protein ligase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer